The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) is a huge mover today! About 229,983 shares traded hands. Aimmune Therapeutics Inc (NASDAQ:AIMT) has risen 73.54% since April 27, 2016 and is uptrending. It has outperformed by 68.32% the S&P500.
The move comes after 5 months negative chart setup for the $1.13B company. It was reported on Nov, 30 by Barchart.com. We have $20.67 PT which if reached, will make NASDAQ:AIMT worth $101.70 million less.
Analysts await Aimmune Therapeutics Inc (NASDAQ:AIMT) to report earnings on March, 2. They expect $-0.47 earnings per share, down 20.51% or $0.08 from last year’s $-0.39 per share. After $-0.53 actual earnings per share reported by Aimmune Therapeutics Inc for the previous quarter, Wall Street now forecasts -11.32% EPS growth.
Aimmune Therapeutics Inc (NASDAQ:AIMT) Ratings Coverage
Out of 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aimmune Therapeutics has been the topic of 5 analyst reports since August 31, 2015 according to StockzIntelligence Inc. The rating was initiated by JMP Securities on Monday, September 26 with “Mkt Outperform”. The company was initiated on Monday, August 31 by Bank of America. The firm has “Overweight” rating by Piper Jaffray given on Monday, August 31. Credit Suisse initiated the stock with “Outperform” rating in Monday, August 31 report. The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) earned “Overweight” rating by Piper Jaffray on Tuesday, November 17.
According to Zacks Investment Research, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California.”
More notable recent Aimmune Therapeutics Inc (NASDAQ:AIMT) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on July 12, 2015, also Businesswire.com with their article: “Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of …” published on November 28, 2016, Businesswire.com published: “Aimmune Therapeutics Completes and Exceeds North American Enrollment Target …” on September 20, 2016. More interesting news about Aimmune Therapeutics Inc (NASDAQ:AIMT) were released by: Quotes.Wsj.com and their article: “News Aimmune Therapeutics Inc.AIMT” published on July 31, 2015 as well as Fiercebiotech.com‘s news article titled: “Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101” with publication date: June 18, 2015.
AIMT Company Profile
Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, incorporated on June 24, 2011, is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.